Loading cancer entity…
Loading cancer entity…
Clinical trials
972 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (145)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05955105 | A Study of ILB2109 and Toripalimab in Patients With Advanced Solid Malignancies | unknown | Phase 1 / Phase 2 | 200 | Innolake BiopharmINDUSTRY | 1 | May 21, 2024 | clinicaltrials |
| NCT03337919 | ANIMATE: Phase II Study of Nivolumab Monotherapy for Relapsed/Refractory Hodgkin Lymphoma(ANIMATE) | unknown | Phase 2 | 78 | University College, LondonOTHER | 1 | May 10, 2024 | clinicaltrials |
| NCT03576378 | BrEPEM-LH-22017 for Older Patients With Untreated Hodgkin Lymphoma (HL) | unknown | Phase 1 / Phase 2 | 41 | Grupo Español de Linfomas y Transplante Autólogo de Médula ÓseaOTHER | 1 | Feb 26, 2024 | clinicaltrials |
| NCT04378647 | BREntuximab Vedotin in SEcond LIne Therapy BEfore Transplant(BRESELIBET) | unknown | Phase 2 | 150 | Grupo Español de Linfomas y Transplante Autólogo de Médula ÓseaOTHER | 1 | Feb 26, 2024 | clinicaltrials |
| NCT06201507 | BV-AVD-R Treatment Children Hodgkin's Lymphoma | unknown | Phase 2 | 44 | Beijing Children's HospitalOTHER | 1 | Jan 12, 2024 | clinicaltrials |
| NCT05757466 | Prolgolimab Monotherapy or in Combination With Bendamustine for r/r Classical Hodgkin Lymphoma(Prolgo-HL) | unknown | Phase 2 | 30 | St. Petersburg State Pavlov Medical UniversityOTHER | 1 | Dec 19, 2023 | clinicaltrials |
| NCT03617666 | Avelumab in the Frontline Treatment of Advanced Classical Hodgkin Lymphoma - a Window Study(AVENuE) | unknown | Phase 2 | 49 | University College, LondonOTHER | 2 | Dec 12, 2023 | clinicaltrials |
| NCT03331731 | A Phase II Study to Determine Pembrolizumab as Frontline Treatment of Patients With Hodgkin Lymphoma(PLIMATH) | unknown | Phase 2 | 27 | Peter MacCallum Cancer Centre, AustraliaOTHER | 2 | Aug 21, 2023 | clinicaltrials |
| NCT05900765 | A Study of Zimberelimab(GLS-010) Combined With AVD for Newly Diagnosed Early-stage Hodgkin's Lymphoma | unknown | Phase 2 | 54 | Sun Yat-sen UniversityOTHER | 1 | Jun 18, 2023 | clinicaltrials |
| NCT05896046 | SHR1701 Alone or in Combination With SHR2554 in Relapsed or Refractory Classical Hodgkin Lymphoma | unknown | Phase 1 / Phase 2 | 100 | Chinese PLA General HospitalOTHER | 1 | Jun 15, 2023 | clinicaltrials |
| NCT03077828 | Pembrolizumab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma | unknown | Phase 2 | 43 | Northwestern UniversityOTHER | 1 | Jun 2, 2023 | clinicaltrials |
| NCT03226249 | PET-Directed Therapy With Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Classical Hodgkin Lymphoma | unknown | Phase 2 | 30 | Northwestern UniversityOTHER | 1 | Jun 2, 2023 | clinicaltrials |
| NCT05833984 | Safety and Efficacy of IMM01 Plus Tislelizumab in Patients With Advanced Solid Tumors and Lymphomas | unknown | Phase 1 / Phase 2 | 309 | ImmuneOnco Biopharmaceuticals (Shanghai) Inc.OTHER | 1 | Apr 27, 2023 | clinicaltrials |
| NCT05660993 | Multicenter Study of Safety and Efficacy of PET-adapted Treatment With Nivolumab, Bendamustine, Gemcitabine, Vinorelbine (Nivo-BeGEV) in Patients With Relapsed/Refractory Hodgkin Lymphoma | unknown | Phase 2 | 50 | National Research Center for Hematology, RussiaNETWORK | 1 | Dec 21, 2022 | clinicaltrials |
| NCT02098512 | Immunotherapy Following Reduced Intensity Conditioning and Allogeneic Stem Cell Transplant for Poor Risk CD30+ Hodgkin Lymphoma Patients | unknown | Phase 1 / Phase 2 | 20 | New York Medical CollegeOTHER | 1 | Oct 27, 2022 | clinicaltrials |
| NCT04624984 | PD-1 Inhibitor or PD-1 Inhibitor Plus GVD for Relapsed/Refractory CHL | unknown | Phase 2 | 42 | Sun Yat-sen UniversityOTHER | 1 | May 9, 2022 | clinicaltrials |
| NCT05137886 | PD-1 Inhibitor Combined With Decitabine Followed by ASCT as Second-line Therapy for Relapsed or Refractory Classic Hodgkin's Lymphoma | unknown | Phase 2 | 47 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Dec 17, 2021 | clinicaltrials |
| NCT04866654 | Radiation Free Chemotherapy for Early Hodgkin Lymphoma(RAFTING) | unknown | Phase 2 | 160 | Medical University of GdanskOTHER | 3 | Aug 12, 2021 | clinicaltrials |
| NCT04653649 | CAR T-cells Against CD30 (HSP-CAR30) for Relapsed/ Refractory Hodgkin and T-cell Lymphoma. | unknown | Phase 1 / Phase 2 | 30 | Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant PauOTHER | 1 | Dec 4, 2020 | clinicaltrials |
| NCT04514081 | The Clinical Trial of Chidamide+Decitabine+Camrelizumab Versus Decitabine+Camrelizumab in Anti-PD-1 Antibody Resistant Patients With Classical Hodgkin Lymphoma. | unknown | Phase 2 | 200 | Chinese PLA General HospitalOTHER | 1 | Aug 18, 2020 | clinicaltrials |
| NCT04233294 | Addition of Chidamide to the Combination Treatment of Decitabine Plus Camrelizumab in Combination Treatment Resistant/Relapsed Patients With Classical Hodgkin Lymphoma | unknown | Phase 2 | 100 | Chinese PLA General HospitalOTHER | 1 | Aug 14, 2020 | clinicaltrials |
| NCT04510610 | Camrelizumab Plus Decitabine in Anti-PD-1 Treatment-naive Patients With Relapsed/Refractory Classical Hodgkin Lymphoma | unknown | Phase 2 / Phase 3 | 100 | Chinese PLA General HospitalOTHER | 1 | Aug 12, 2020 | clinicaltrials |
| NCT03474133 | Brentuximab Vedotin as Alternative to the Autologous Stem Cell Transplantation in Relapsed and Refractory Classical Hodgkin's Lymphoma (BASALT)(BASALT) | unknown | Phase 2 | 80 | Federal Research Institute of Pediatric Hematology, Oncology and ImmunologyOTHER | 1 | Jul 21, 2020 | clinicaltrials |
| NCT04239170 | Camrelizumab(SHR-1210) Combined With GEMOX in Patients With Relapsed or Refractory Hodgkin Lymphoma | unknown | Phase 2 | 84 | Peking UniversityOTHER | 1 | Jan 23, 2020 | clinicaltrials |
| NCT03527628 | OPTmizing Advanced Stage HodgkIn LymphoMa patIentS Therapy((Optimist)) | unknown | Phase 2 | 220 | King Abdullah International Medical Research CenterOTHER | 1 | Nov 18, 2019 | clinicaltrials |
| NCT04026269 | Clinical Efficacy of MOAP Regimen for Relapsed/Refractory cHL as a Rescue Therapy After DP Regimen | unknown | Phase 1 / Phase 2 | 30 | Han weidongOTHER | 1 | Jul 19, 2019 | clinicaltrials |
| NCT03250962 | SHR-1210 Alone or in Combination With Decitabine in Relapsed or Refractory Hodgkin Lymphoma | unknown | Phase 2 | 280 | Chinese PLA General HospitalOTHER | 1 | Apr 1, 2019 | clinicaltrials |
| NCT03602131 | Chidamide Combined With Clad/Gem/Bu With AutoSCT in High Risk Hodgkin & Non-Hodgkin Lymphoma | unknown | Phase 2 | 30 | Sichuan UniversityOTHER | 0 | Jul 26, 2018 | clinicaltrials |
| NCT03540849 | BV After Allogeneic Hematopoietic Stem Cell Transplantation(BV-ALLO) | unknown | Phase 2 | 58 | University Hospital, CaenOTHER | 1 | May 30, 2018 | clinicaltrials |
| NCT03091933 | Antiminor Histocompatibility Complex (MiHA) T Cells for Patients With Relapsed Hematologic Malignancies Following Matched HSCT (Guided Lymphocyte Immunopeptide Derived Expansion)(GLIDE) | unknown | Phase 1 / Phase 2 | 20 | Ciusss de L'Est de l'Île de MontréalOTHER | 1 | Dec 6, 2017 | clinicaltrials |
| NCT03244930 | Low Dose Plerixafor Plus G-CSF in Mobilizing Stem Cells for Autologous Peripheral Blood Transplantation | unknown | Phase 2 | 20 | Hospital Universitario Dr. Jose E. GonzalezOTHER | 1 | Aug 10, 2017 | clinicaltrials |
| NCT03044743 | PD-1 Knockout EBV-CTLs for Advanced Stage Epstein-Barr Virus (EBV) Associated Malignancies | unknown | Phase 1 / Phase 2 | 20 | Yang YangOTHER | 1 | May 2, 2017 | clinicaltrials |
| NCT01079013 | Treosulfan-based Conditioning for Allogeneic Stem-cell Transplantation (SCT) in Lymphoid Malignancies | unknown | Phase 2 | 40 | Sheba Medical CenterOTHER_GOV | 1 | Apr 20, 2016 | clinicaltrials |
| NCT02507479 | Thiotepa-based Conditioning for Allogeneic Stem-cell Transplantation (SCT) in Lymphoid Malignancies | unknown | Phase 2 | 24 | Sheba Medical CenterOTHER_GOV | 1 | Apr 20, 2016 | clinicaltrials |
| NCT00795613 | Positron Emission Tomography (PET)-Adapted Chemotherapy In Advanced Hodgkin Lymphoma (HL)(HD0607) | unknown | Phase 2 | 450 | Ospedale Santa Croce-Carle CuneoOTHER | 2 | Oct 19, 2015 | clinicaltrials |
| NCT01412307 | A Phase 1/2 Study of Lenalidomide in Combination With Bendamustine in Relapsed and Primary Refractory Hodgkin Lymphoma(LEBEN) | unknown | Phase 1 / Phase 2 | 36 | Istituto Nazionale Tumori IRCCS - Fondazione G. PascaleNETWORK | 1 | Aug 11, 2015 | clinicaltrials |
| NCT02275598 | Brentuximab Vedotin Followed by ABVD in Patients With Previously Untreated Hodgkin Lymphoma | unknown | Phase 2 | 12 | University of Modena and Reggio EmiliaOTHER | 1 | Oct 27, 2014 | clinicaltrials |
| NCT02007811 | Open-label Clinical Trial to Investigate the Safety and Tolerability of Allogeneic B-cell Concentrates for Immune Reconstitution After Allogeneic Stem Cell Transplantation Measured as Response to a Antedated Single Vaccination(B-cell therapy) | unknown | Phase 1 / Phase 2 | 15 | University of Erlangen-Nürnberg Medical SchoolOTHER | 1 | Mar 26, 2014 | clinicaltrials |
| NCT01884441 | Bendamustine, Gemcitabine and Vinorelbine (BeGEV) as Induction Therapy in Relapsed/Refractory Hodgkin's Lymphoma Patients | unknown | Phase 2 | 59 | Armando Santoro, MDOTHER | 1 | Jan 29, 2014 | clinicaltrials |
| NCT01983761 | Study of ASC-101 in Patients With Hematologic Malignancies Who Receive Dual-cord Umbilical Cord Blood Transplantation | unknown | Phase 1 / Phase 2 | 25 | Targazyme, Inc.INDUSTRY | 1 | Nov 18, 2013 | clinicaltrials |
| NCT01333605 | IGEV Followed by Autologous Transplantation for Refractory or Relapsed Hodgkin Lymphoma | unknown | Phase 2 | 43 | Fudan UniversityOTHER | 1 | Mar 5, 2013 | clinicaltrials |
| NCT00797472 | Study Comparing R-mabHD and a Combination of ABVD in Hodgkin's Disease | unknown | Phase 2 | 120 | American Scitech InternationalOTHER | 1 | Jul 20, 2011 | clinicaltrials |
| NCT01300156 | Etoposide, Methylprednisolone, High-dose Cytarabine and Oxaliplatin (ESHAOx) for Refractory or Relapsed Hodgkin's Lymphoma (HL) | unknown | Phase 2 | 37 | National Cancer Center, KoreaOTHER_GOV | 1 | Feb 21, 2011 | clinicaltrials |
| NCT00179816 | Tandem Peripheral Blood Stem Cell (PBSC) Rescue for High Risk Solid Tumors | unknown | Phase 1 / Phase 2 | 12 | Ann & Robert H Lurie Children's Hospital of ChicagoOTHER | 1 | Oct 11, 2010 | clinicaltrials |
| NCT00598624 | Clinical Trial to Evaluate the Safety and Efficacy of Treosulfan Based Conditioning Prior to Allogeneic Haematopoietic Stem Cell Transplantation (HSCT)(AlloTreo) | unknown | Phase 2 | 175 | IRCCS San RaffaeleOTHER | 1 | Aug 11, 2009 | clinicaltrials |
| NCT00441818 | Safety and Efficacy Study of TNX-650 to Treat Refractory Hodgkin's Lymphoma | unknown | Phase 1 / Phase 2 | 59 | TanoxINDUSTRY | 1 | May 9, 2008 | clinicaltrials |
Data updated 22 days agoSource updated May 21, 2024source: clinicaltrials